Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals Ends FY2024 On Solid Footing
ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see solid growth from its two products on the market and has also build up a large amount of net cash on its balance sheet. ACADIA Pharmaceuticals is also advancing several key assets within its developmental pipeline.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kulkarni - Canaccord Genuity LLC Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Shannon, and I will be your coordinator for today.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
